High-dose thalidomide increases the risk of peripheral neuropathy in the treatment of ankylosing spondylitis.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 4468777)

Published in Neural Regen Res on May 01, 2015

Authors

Hong-Xia Xue1, Wen-Yi Fu1, Hua-Dong Cui1, Li-Li Yang1, Ning Zhang1, Li-Juan Zhao2

Author Affiliations

1: Department of Rheumatology and Immunology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.
2: Department of Rheumatology and Immunology, the First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China.

Articles cited by this

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum (2000) 4.62

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med (1991) 4.43

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med (1998) 2.39

Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol (2002) 1.96

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79

Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum (2001) 1.68

Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol (1994) 1.57

Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum (2005) 1.46

Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 1.35

Thalidomide: a review of approved and investigational uses. Clin Ther (2003) 1.26

Activation of nuclear factor-kappaB via endogenous tumor necrosis factor alpha regulates survival of axotomized adult sensory neurons. J Neurosci (2005) 1.11

Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol (2002) 1.05

Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus (2005) 0.91

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol (2005) 0.91

One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum (2002) 0.87

Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis. Joint Bone Spine (2007) 0.86

Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol (2014) 0.84

Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept. Rheumatol Int (2012) 0.83

Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol (2003) 0.80

Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus. Autoimmunity (2005) 0.79

Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease. Clin Rheumatol (2007) 0.79

The antiangiogenic effect of thalidomide on occult liver metastases: an in vivo study in mice. J Gastroenterol Hepatol (2009) 0.78

Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leuk Lymphoma (2014) 0.78

[The efficacy and safety of long-term thalidomide in the treatment of ankylosing spondylitis]. Zhonghua Nei Ke Za Zhi (2010) 0.77

Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity. Int J Dermatol (2013) 0.77

A pilot study on changes of macrophage colony stimulating factor and transforming growth factor beta1 in male patients with ankylosing spondylitis taking thalidomide. Ann Rheum Dis (2009) 0.77